TE HANGARAU WHAKAMUTUNGA O BEIJING INC.

Me tūpato te hunga e tango ana i ngā rongoā whakaheke toto i te wā e kai ana i ngā panana. Ka āwhina a Beijing Succeeder ki te tautuhi i te toto toto me te toto toto.

E kiia ana te panana he hua hauora nā te nui o ngā kai totika, tae atu ki ngā huaora me ngā kohuke. Heoi, mō te hunga e tango ana i ngā rongoā whakaheke toto, tera pea he tūponotanga huna mō te hauora o te panana.

Ko ngā rongoā whakangawari toto, pērā i te warfarin noa, e whakamahia ana hei ārai me te rongoā i ngā mate toto toto. Ko ngā tūroro e pāngia ana e ngā āhuatanga pēnei i te pokanga whakakapinga takirere ngākau, te fibrillation atrial, me te thrombosis uaua o raro o te waewae me whakamahi mō te wā roa. Ko tā rātou tikanga mahi he aukati i te whakahohenga o ngā take toto toto e whakawhirinaki ana ki te huaora K, ā, ka whakaiti i te mōrearea o te toto toto toto me te whakarite i te rere o te toto kia maeneene. He hua nui te panana i roto i te huaora K, tata ki te 10 maikirokaramu ia 100 karamu. Ka mahi te huaora K hei "whakaoho" i te pūnaha toto toto toto, e whakatairanga ana i te whakahohenga o ngā take toto toto toto toto me te tere ake o te toto toto toto toto. Ina kai ngā tūroro e tango ana i ngā rongoā whakangawari toto ...

Heoi, ehara tēnei i te kī me karo rawa te hunga e tango ana i ngā rongoā whakaheke toto i ngā panana. E ai ki te "Dietary Guidelines for Chinese Residents" (2022), me kai e ngā pakeke te 200-350 karamu o ngā hua i ia rā, tata ki te kotahi ki te rua panana. Ko te kai taurite kāore e pā nui ki te whai huatanga o ngā rongoā whakaheke toto. Heoi, ko te mea nui ko te pupuri i tētahi kai taurite me te pumau, me te karo i ngā rerekētanga nui o te kai huaora K i roto i ngā wā poto.

Ko Beijing Succeeder Technology Inc. (waehere hea: 688338) he kaiārahi i roto i te mara o te tātaritanga in vitro mō te thrombosis me te hemostasis. I whakatūria i te tau 2003, kua roa te kamupene e arotahi ana ki te rangahau, te whakawhanake, te whakaputa, me te hoko i ngā taputapu tātaritanga in vitro me ngā matū mō te thrombosis me te hemostasis. Ka whakaratohia e Beijing Succeeder ki ngā whare hauora ngā taputapu whakamātautau aunoa, tae atu ki te coagulation, te hemorheology, te hematocrit, me te platelet aggregation, tae atu ki ngā matū tautoko me ngā mea pau. He whānuitia te whakamahinga o ana hua ki te aukati, te tirotiro, te tātaritanga, me te aroturuki i ngā mate thrombotic me te hemorrhagic, tae atu ki te whiu, te mate uaua coronary, me te venous thromboembolism.

I te tau 2023, i whiwhi te mīhini tātari toto toto aunoa a Beijing Succeeder i te rēhitatanga IVDR CE, e whakaatu ana i tōna kaha hangarau me te kounga hua i roto i te mara tātaritanga in vitro. Ko ngā raraunga i tukuna i te 17 o Ākuhata o taua tau anō i whakaatu i whiwhi te kamupene i te moni whiwhi whakahaere o te 141 miriona yuan i te haurua tuatahi o te tau, he pikinga tau-ki-te-tau o te 33.19%, me te hua kupenga e taea ana e ngā kaipupuri hea o te 60.222 miriona yuan, he pikinga tau-ki-te-tau o te 26.91%. I tua atu, kua whiwhi a Beijing Succeeder i ngā tohu maha, tae atu ki te whiriwhiringa mō te Rārangi Hinonga Hangarau-High-Tech Key Program 2012 i whakaputaina e te Torch Center o te Manatū Pūtaiao me te Hangarau, me te tūnga 29 i roto i te 2022 China In Vitro Diagnostic Industry Listed Company Net Profit Ranking.

Mā ngā hua me ngā hangarau ngaio a Beijing Succeeder e tautoko ngā tākuta ki te aromatawai tika i te āhua toto toto o ngā tūroro, he mea nui tēnei ki te tiaki i te hauora o ngā tūroro. Mō ngā tūroro e tango ana i ngā rongoā whakangawari toto, mā te aroturuki tonu me ngā hangarau me ngā hua whakamātautau matatau, me te aro hoki ki ngā taunekeneke kai me ngā rongoā, ka pai ake te whakarite i te whai huatanga o te maimoatanga me te hauora whānui.